Guidelines for time-to-event end-point definitions in adjuvant randomised trials for patients with localised colon cancer: Results of the DATECAN initiative.

[1]  N. Tomita,et al.  A randomised-controlled trial of 1-year adjuvant chemotherapy with oral tegafur-uracil versus surgery alone in stage II colon cancer: SACURA trial. , 2018, European journal of cancer.

[2]  A. Briggs,et al.  3 versus 6 months of adjuvant oxaliplatin-fluoropyrimidine combination therapy for colorectal cancer (SCOT): an international, randomised, phase 3, non-inferiority trial , 2018, The Lancet. Oncology.

[3]  R. Labianca,et al.  Duration of Adjuvant Chemotherapy for Stage III Colon Cancer , 2018, The New England journal of medicine.

[4]  L. Thygesen,et al.  Antenatal small-class education versus auditorium-based lectures to promote positive transitioning to parenthood – A randomised trial , 2017, PloS one.

[5]  Jianming Xu,et al.  Randomized Controlled Trial of Intraportal Chemotherapy Combined With Adjuvant Chemotherapy (mFOLFOX6) for Stage II and III Colon Cancer , 2016, Annals of surgery.

[6]  F. Retornaz,et al.  PRODIGE 34-FFCD 1402-ADAGE: Adjuvant chemotherapy in elderly patients with resected stage III colon cancer: A randomized phase 3 trial. , 2016, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[7]  C. Porta,et al.  Guidelines for the definition of time-to-event end points in renal cell cancer clinical trials: results of the DATECAN project†. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[8]  Y. Kakeji,et al.  Randomized phase III trial of treatment duration for oral uracil and tegafur plus leucovorin as adjuvant chemotherapy for patients with stage IIB/III colon cancer: final results of JFMC33-0502 , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[9]  A. Luciani,et al.  Neoadjuvant FOLFOX 4 versus FOLFOX 4 with Cetuximab versus immediate surgery for high-risk stage II and III colon cancers: a multicentre randomised controlled phase II trial – the PRODIGE 22 - ECKINOXE trial , 2015, BMC Cancer.

[10]  S Michiels,et al.  Guidelines for time-to-event end point definitions in breast cancer trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials)†. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[11]  S. Sleijfer,et al.  Guidelines for time-to-event end point definitions in sarcomas and gastrointestinal stromal tumors (GIST) trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials)†. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[12]  Karin Haustermans,et al.  Guidelines for time-to-event end-point definitions in trials for pancreatic cancer. Results of the DATECAN initiative (Definition for the Assessment of Time-to-event End-points in CANcer trials). , 2014, European journal of cancer.

[13]  N. Tomita,et al.  Randomised phase III trial of adjuvant chemotherapy with oral uracil and tegafur plus leucovorin versus intravenous fluorouracil and levofolinate in patients with stage III colorectal cancer who have undergone Japanese D2/D3 lymph node dissection: final results of JCOG0205. , 2014, European journal of cancer.

[14]  L. Collette,et al.  Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial. , 2014, The Lancet. Oncology.

[15]  N. Tomita,et al.  S-1 as adjuvant chemotherapy for stage III colon cancer: a randomized phase III study (ACTS-CC trial) , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[16]  A. Carrato,et al.  A randomised phase III intergroup trial comparing high-dose infusional 5-fluorouracil with or without folinic acid with standard bolus 5-fluorouracil/folinic acid in the adjuvant treatment of stage III colon cancer: the Pan-European Trial in Adjuvant Colon Cancer 2 study. , 2013, European journal of cancer.

[17]  Thomas Filleron,et al.  Protocol of the Definition for the Assessment of Time-to-event Endpoints in CANcer trials (DATECAN) project: formal consensus method for the development of guidelines for standardised time-to-event endpoints' definitions in cancer clinical trials. , 2013, European journal of cancer.

[18]  N. Petrelli,et al.  Bevacizumab in stage II-III colon cancer: 5-year update of the National Surgical Adjuvant Breast and Bowel Project C-08 trial. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  J. Hecht,et al.  Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial. , 2012, The Lancet. Oncology.

[20]  W. Scheithauer,et al.  Capecitabine versus 5-fluorouracil/folinic acid as adjuvant therapy for stage III colon cancer: final results from the X-ACT trial with analysis by age and preliminary evidence of a pharmacodynamic marker of efficacy. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[21]  D. Sargent,et al.  Effect of oxaliplatin, fluorouracil, and leucovorin with or without cetuximab on survival among patients with resected stage III colon cancer: a randomized trial. , 2012, JAMA.

[22]  Bengt Glimelius,et al.  Survival endpoints in colorectal cancer and the effect of second primary other cancer on disease free survival , 2011, BMC Cancer.

[23]  N. Petrelli,et al.  Oxaliplatin as adjuvant therapy for colon cancer: updated results of NSABP C-07 trial, including survival and subset analyses. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  D. Kerr,et al.  Documenting the natural history of patients with resected stage II adenocarcinoma of the colon after random assignment to adjuvant treatment with edrecolomab or observation: results from CALGB 9581. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  F. D. De Braud,et al.  Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage III colon cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  S. Yoshida,et al.  Final results of randomized trials by the National Surgical Adjuvant Study of Colorectal Cancer (NSAS-CC) , 2011, Cancer Chemotherapy and Pharmacology.

[27]  M. Dimopoulos,et al.  A randomized phase III trial of adjuvant chemotherapy with irinotecan, leucovorin and fluorouracil versus leucovorin and fluorouracil for stage II and III colon cancer: A Hellenic Cooperative Oncology Group study , 2011, BMC medicine.

[28]  D. Moher,et al.  CONSORT 2010 Statement: updated guidelines for reporting parallel group randomized trials , 2010, Obstetrics and gynecology.

[29]  R. Greil,et al.  Randomized phase III trial comparing biweekly infusional fluorouracil/leucovorin alone or with irinotecan in the adjuvant treatment of stage III colon cancer: PETACC-3. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  T. Hickish,et al.  Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  T. Conroy,et al.  A phase III randomised trial of LV5FU2 + irinotecan versus LV5FU2 alone in adjuvant high-risk colon cancer (FNCLCC Accord02/FFCD9802). , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

[32]  K. Rufibach,et al.  Perioperative and adjuvant chemotherapy in colon cancer: results of SAKK trial 40/93 , 2009, International Journal of Colorectal Disease.

[33]  B. Vonen,et al.  Final results of a randomised phase III study on adjuvant chemotherapy with 5 FU and levamisol in colon and rectum cancer stage II and III by the Norwegian Gastrointestinal Cancer Group , 2009, Acta oncologica.

[34]  R. Labianca,et al.  Raltitrexed (Tomudex) versus standard leucovorin-modulated bolus 5-fluorouracil: Results from the randomised phase III Pan-European Trial in Adjuvant Colon Cancer 01 (PETACC-1). , 2008, European journal of cancer.

[35]  R. Greil,et al.  A prospective randomised phase III trial of adjuvant chemotherapy with 5-fluorouracil and leucovorin in patients with stage II colon cancer , 2007, British Journal of Cancer.

[36]  M. Buyse,et al.  Phase III study comparing a semimonthly with a monthly regimen of fluorouracil and leucovorin as adjuvant treatment for stage II and III colon cancer patients: final results of GERCOR C96.1. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  R. Goldberg,et al.  Irinotecan fluorouracil plus leucovorin is not superior to fluorouracil plus leucovorin alone as adjuvant treatment for stage III colon cancer: results of CALGB 89803. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  R. Labianca,et al.  Endpoints in adjuvant treatment trials: a systematic review of the literature in colon cancer and proposed definitions for future trials. , 2007, Journal of the National Cancer Institute.

[39]  N. Petrelli,et al.  Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[40]  M. Ohue,et al.  Capecitabine versus S-1 as adjuvant chemotherapy for patients with stage III colorectal cancer (JCOG0910): an open-label, non-inferiority, randomised, phase 3, multicentre trial. , 2018, The lancet. Gastroenterology & hepatology.

[41]  R. Guy,et al.  International Conference on Harmonisation , 2014 .

[42]  International conference on harmonisation; guidance on statistical principles for clinical trials; availability--FDA. Notice. , 1998, Federal register.

[43]  K M Leung,et al.  Censoring issues in survival analysis. , 1997, Annual review of public health.